Core Insights - Codexis Inc. shares increased by 37.8% in after-hours trading to $1.75 following the release of its fourth-quarter and full-year 2025 earnings [1] Group 1: Q4 Profit Swing and Revenue Beat - Codexis reported a fourth-quarter net income of $9.6 million, or 11 cents per share, reversing a loss of $10.4 million, or 13 cents per share, from the same period a year earlier [2] - Total fourth-quarter revenue rose by 81% to $38.9 million, up from $21.5 million in Q4 2024, exceeding analyst estimates of $36.82 million by 5.69% [2] - The company achieved a product gross margin of 65% for the quarter, an increase from 63% a year earlier [2] Group 2: Full-Year Results and 2026 Outlook - For the full year of fiscal 2025, Codexis' revenues increased by 19% to $70.4 million [3] - The net loss narrowed to $44 million, or $0.50 per share, compared to a loss of $65.3 million, or $0.89 per share, in 2024 [3] - As of December 31, 2025, the company held $78.2 million in cash, cash equivalents, and short-term investments, with guidance for 2026 revenues projected between $72 million and $76 million [3] Group 3: Future Plans - Codexis is targeting a pharmaceutical licensing deal in the second half of 2026 [4] Group 4: Trading Metrics and Technical Analysis - The market capitalization of Codexis is $114.71 million, with a 52-week trading range of $3.87 to $0.96 [5] - The stock has a Relative Strength Index (RSI) of 52.87 and has decreased by 53.99% over the past 12 months [5] - Currently, the stock is approximately 10.7% above its 52-week low, indicating a position near the bottom of its yearly range [6]